Table 2. Association with clinicopathological findings.

	Months after first sample
Patient	0	1	2	3	4	5	6	7	8	9	10	11	12	13
No. 11FS 3Ex 10	Gly	Gly	Val	NA	Val	Val	Val	Val	←Ki-ras status in plasma
	2654	2706	5288	>104	8077	NA	>104		←CA 19-9 level in serum (U ml−1)
	GFF	GFF	Tax	Tax	Tax	Tax	Tax	Tax	←(Chemo-) therapy
	NC		PD						←Imaging
No. 13FS 0Ex 7	Gly	NA	Gly	NA	Gly	Gly	Gly
	6879	NA	698	654	2254	>104	>104
	Gem	Gem	Gem	Gem	Gem	Gem	OFF
				PR		PD
No. 16FS 22Ex 35	Gly	NA	Gly	NA	Gly	NA	Gly	Gly	Gly	Gly	Gly	NA	Gly	Gly
	109	62	43	NA	45	90	NA	191	340	426	1948	NA	4216	NA
	OFF	OFF	OFF	OFF	OFF	OFF	OFF	OFF	OFF	OFF	OFF	OFF	Gem	Gem
				NC				NC					PD
No. 29FS 2Ex 5	Gly	Gly	Gly	NA
	1	NA	9	32
	Gem	OFF		OFF
	PD			PD
No. 34FS 1Ex 8	Gly	NA	Gly	Gly	Mut	Mut	Mut
	5916	2291	4169	>104	>104	>105	NA
	Gem	Gem	Gem	Gem	Gem	OFF	OFF
			PR		PD
No. 37FS 11Ex 23	Gly	NA	Gly	NA	Gly	Gly	Gly	Gly	Gly	Gly	Gly
	7	NA	13	NA	28	37	NA	41	50	52	56
	Tax	Tax	Tax	Tax	Tax	Tax	Tax	Tax	Tax	Tax	Tax
No. 38FS 1Ex 5	Gly	Gly	Gly	Gly
	>106	>106	NA	>106
	Gem	Gem	OFF	OFF
			PD
No. 39FS 82Ex 83	Gly	Val
	>104	>104
	Gem	Gem
	PD
No. 40FS 31Ex 43	Gly	NA	NA	Gly	NA	Gly	Gly	Gly	Gly	Gly	Gly	NA	Gly
	NA	NA	309	NA	NA	464	NA	179	NA	NA	218	NA	251
	Gem	Gem	Gem	Gem	OFF				Tax	Tax	Tax
				PD
No. 43FS 1Ex 14	Val	NA	NA	Val	Val	Val	Val	Val	Val	Val	Val	NA	NA
	677	NA	434	1365	2116	5231	883	446	544	1506	>104	>104
	GFF	GFF	GFF	GFF	GFF	Tax	Tax	Tax	Tax	Tax	Tax
				PD					PR

FS=time of 1st collected sample after diagnosis (in months); Ex=death in months after collection of the 1st sample; NA=no data available; Gly=glycine (wild type); Val=valine (mutation); Mut=mutation different from valine; GFF=gemcitabine+5-fluorouracil+folinic acid; Gem=gemcitabine mono; Tax=taxol; OFF=oxaliplatin+5-fluorouracil+folinic acid; NC=no change; PD=progressive disease; PR=partial regression.